GlassScriptPhysician profile
Puniya Khatiwada
NPI 1487946562
$4,366.66
in general payments reported to CMS, 2019-2025
36 companies · $226 in 2025
The $226 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $79.66 · 2022: $1,435 · 2023: $2,503 · 2024: $123 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,851.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $577.49 | 2022-2024 | Jardiance, Mounjaro, Lyumjev |
| Novo Nordisk INC | $553.65 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Sanofi-Aventis U.S. LLC | $343.29 | 2022-2023 | |
| Amneal Pharmaceuticals LLC | $326.90 | 2022-2023 | Unithroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.16 | 2022-2024 | Jardiance |
| Xeris Pharmaceuticals, INC. | $209.57 | 2022-2023 | Recorlev, Gvoke Hypopen |
| Corcept Therapeutics | $201.28 | 2022-2023 | Korlym |
| Radius Health, INC. | $175.08 | 2022-2025 | Tymlos |
| Dexcom, INC. | $166.30 | 2023-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $150.14 | 2022-2024 | |
| Amgen INC. | $133.17 | 2022-2025 | Evenity, Prolia |
| Astellas Pharma US INC | $115.61 | 2023 | Veozah |
| Amryt Pharma Holdings LTD | $108.05 | 2022-2023 | Mycapssa |
| Insulet Corporation | $106.45 | 2022-2024 | Omnipod |
| Alexion Pharmaceuticals, INC. | $81.64 | 2022-2023 | Strensiq |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $79.66 | 2020 | |
| Ascensia Diabetes Care US INC. | $72.59 | 2022-2023 | |
| Recordati_rare_diseases_inc. | $71.07 | 2022-2023 | Isturisa, Signifor Lar |
| Antares Pharma, INC. | $62.89 | 2022-2023 | Nocdurna, Tlando, Xyosted |
| Abbott Laboratories | $60.08 | 2022-2023 | Freestyle Libre 3 |
| Embecta Corp. | $59.25 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Tandem Diabetes Care, INC. | $58.64 | 2022-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Halozyme INC | $47.65 | 2023 | |
| Ascendis Pharma Endocrinology INC | $46.09 | 2023 | |
| Mannkind Corporation | $43.33 | 2022-2023 | Afrezza |
| Abbvie INC. | $43.31 | 2022 | |
| Pfizer INC. | $38.49 | 2022-2023 | |
| Azurity Pharmaceuticals, INC. | $33.18 | 2023 | Adthyza |
| Becton, Dickinson and Company | $31.02 | 2022 | |
| Tolmar, INC. | $30.34 | 2023 | |
| Kyowa Kirin, INC. | $23.61 | 2023 | Crysvita |
| Amarin Pharma, INC. | $23.28 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.99 | 2023 | |
| Eusa Pharma (US) LLC | $20.92 | 2022 | |
| Horizon Therapeutics Plc | $20.77 | 2023 | Tepezza |
| Ultragenyx Pharmaceutical INC. | $17.72 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Puniya Khatiwada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.